

DOCKET NO.: D0617.70002US10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Robert Charles Ladner et al.

Serial No.:

09/893,878

Confirmation No.:

1764

Filed:

June 29, 2001

For:

DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS

Examiner:

Padmashri Ponnaluri

Art Unit:

1639

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 27th day of October, 2005.

Helissa L. Barlow Lyons

Melissa L. Barlow Lyons

MAIL STOP Amendment

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- **Amendment**
- Sequence Listing 3 CDR's
- Statement Under 37 C.F.R. §1.821(g)
- Petition for 3-month Extension of Time
- **Copy of Notice to Comply**
- **Return Receipt Postcard**

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check in the amount of \$1020.00 is enclosed to cover the three month extension of time fee. If the fee is insufficient, the balance may be charged to Deposit Account 23/2825. A duplicate of this sheet is enclosed.

> Respectfully Submitted, Robert Charles Ladner et al., Applicants

MaryDilys S. Anderson, Reg. No. 52,560

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2211

Telephone: (617)646-8000

Docket No.: D0617.70002US10

Date: October 27, 2005 x10/27/05x



Notice to Comply

Application No.	Applicant(s)
09/893,878	1
Examiner	Art Unit
CELSA, BENNETT	1639

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
☐ 7. Other: Amino acid sequences listed in claims
Applicant Must-Provide: ☑ An initial of substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (571) 272-2510 For CRF Submission Help, call (571) 272-2501/2583.
Patentin Software Program Support
Technical Assistance703-287-0200 To Purchase Patentin Software703-306-2600
10 Fulchase Falentin Sultware/03*300*2000

the page obtained from Pau 07/01/05 &

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY